focus -WSS

focus

author：leisure time 2025-09-28 00:49:16 - browse：613

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially recommending against approving the company’s ALS treatment — the latest potential turning point for a drug that has seen its share of ups and downs with regulatory bodies.

In June, a European Medicines Agency committee issued a negative review of Amylyx’s drug, called Albrioza, and cast doubt on whether it had demonstrated effectiveness in its pivotal study. That would have almost certainly led to a rejection by regulators, but Amylyx requested what’s called a re-examination of the opinion. On Tuesday, the EMA held a meeting on the appeal, and a decision is expected in the coming weeks.

“There are patients who are dying and they really want access to the drug,” said Evy Reviers, the chairwoman of the European Organization for Professionals and Patients with ALS, whose father has the neurological disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Use doctors trained outside the U.S. to ease the physician shortage

focus

knowledge

WSS

Indian pharmaceutical industry in denial over drug

Tesla recalling nearly 16,000 of its 2021

How Robert F. Kennedy Jr. distorted vaccine science

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Hospitals struggle to profit from CAR

Crowdfunding for unproven stem cell procedures spreads misinformation

knowledge

focus

hotspot

Alkermes shareholders re

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Apple is now the first public company to be valued at $3 trillion

AstraZeneca lung cancer study comes in below expectations

Malaria cases in Florida and Texas: Here’s what you need to know

Lupron, used to halt puberty in children, may cause lasting health problems

The high cost of giving birth even with insurance

Hospitals struggle to profit from CAR

focus

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

'Screen and refer' systems are hurting patients

Being 'nonadherent' patient made me a more empathetic doctor

Crowdfunding for unproven stem cell procedures spreads misinformation

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Prescription digital therapeutics are key to pharma’s future

focus

knowledge

knowledge

focus